Ulcerative colitis (UC) is a chronic inflammatory bowel disease characterized by recurrent intestinal inflammation, abdominal ...

Explore the latest advancements in treating ulcerative colitis using machine learning to discover new antimicrobial peptides.

The American Gastroenterological Association has updated guidance for the treatment of ulcerative colitis to recommend using higher efficacy drugs in earlier stages of treatment, Medscape Medical News ...

For people with UC, ‘feeling better’ is just the start. Learn why tissue-level (histological) healing is becoming the new ...

A machine learning-based computational approach to accelerate therapeutic discoveryUlcerative colitis (UC) is a chronic inflammatory bowel disease ...

Ulcerative colitis (UC) is a chronic, immune-mediated inflammatory disorder of the colon that follows a relapsing-remitting ...

Switching UC treatments while managing a career and home life can be a major challenge. Here’s how to navigate work logistics, family communication, and side effects.

Please provide your email address to receive an email when new articles are posted on . A greater proportion of patients in the PRA023 group achieved clinical remission at 12 weeks vs. placebo (26.5% ...

How Does Tremfya Work for Ulcerative Colitis? Tremfya is a monoclonal antibody that reduces inflammation. The main ingredient in Tremfya is a medicine called guselkumab. This medicine blocks a ...

The MarketWatch News Department was not involved in the creation of this content. Ulcerative Colitis Market Poised for Strong Expansion During the Forecast Period (2025-2034) Driven by Biologic and ...

Nearly 70% of adolescents and young adults stop taking oral 5-aminosalicylic acid (5-ASA) maintenance therapy within 12 months of ulcerative colitis (UC) diagnosis, new research from the United ...